Non-Alcoholic Steatohepatitis Biomarkers Market Report 2026

Non-Alcoholic Steatohepatitis Biomarkers Market Overview

• Non-Alcoholic Steatohepatitis Biomarkers market size has reached to $1.68 billion in 2025 • Expected to grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 22% • Growth Driver: Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market • Market Trend: Innovative Biomarker-Based Test Receives FDA Breakthrough Designation for Fibrosis Assessment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Alcoholic Steatohepatitis Biomarkers Market?

Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment. The main types of non-alcoholic steatohepatitis biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers and others. Hepatic fibrosis biomarkers refer to biomarkers for hepatic fibrosis, an overly exuberant wound healing in which excessive connective tissue develops in the liver. They are used to treat different diseases including hypertension, heart disease, high blood lipid, type 2 diabetes and obesity for use by various end-uses such as research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics and others.

What Is The Non-Alcoholic Steatohepatitis Biomarkers Market Growth Forecast?

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 22.0%. The growth in the forecast period can be attributed to increasing investments in precision hepatology, rising demand for non-invasive diagnostic tools, expansion of biomarker-driven clinical trials, growing adoption of personalized medicine approaches, increasing focus on early-stage disease management. Major trends in the forecast period include increasing development of non-invasive diagnostic biomarkers, rising use of serum-based nash biomarkers, growing integration of ai in biomarker analysis, expansion of companion diagnostics in drug development, enhanced focus on early disease detection.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types 2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies 3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses Subsegments: 1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index 2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin 3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP) 4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP) 5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers

What Is The Driver Of The Non-Alcoholic Steatohepatitis Biomarkers Market?

The growing prevalence of liver cancer is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Liver cancer refers to the development of malignant tumors within the liver and can start in the liver itself (primary liver cancer) or spread to the liver from other parts of the body (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are used in liver cancer for early detection, disease progression monitoring, and treatment response assessment, to provide prognostic information, and can help reduce the need for invasive procedures. For instance, in July 2025, according to the ecancer medical science, a UK-based cancer journal, earlier projections indicate that new liver cancer cases are expected to almost double from 870,000 in 2022 to 1.52 million by 2050, driven mainly by population growth and ageing, with the steepest rises anticipated in Africa. Liver cancer deaths are also projected to increase from 760,000 in 2022 to 1.37 million by 2050. Therefore, the growing prevalence of liver cancer is driving the growth of the non-alcoholic steatohepatitis biomarkers industry.

Key Players In The Global Non-Alcoholic Steatohepatitis Biomarkers Market

Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

Global Non-Alcoholic Steatohepatitis Biomarkers Market Trends and Insights

Major companies operating in the non-alcoholic steatohepatitis biomarkers market are incorporating advanced biomarker-platform technologies such as multi-analyte fibrosis-scoring assays to enhance non-invasive disease assessment and patient risk stratification. These assays measure multiple fibrosis-related proteins in a single blood sample and use an algorithm to generate a numerical score, enabling prognostic evaluation and support for identifying advanced fibrosis. For instance, in July 2023, Siemens Healthineers, a Germany-based medical-technology company, received breakthrough device designation from the US Food and Drug Administration for the Enhanced Liver Fibrosis Test, a multi-analyte fibrosis-scoring assay intended to support identification of advanced fibrosis and cirrhosis in individuals with non-alcoholic fatty liver disease, featuring a numerical score derived from three direct fibrosis biomarkers. The test supports earlier clinical evaluation of liver disease severity and reduces reliance on invasive biopsy.

What Are Latest Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Biomarkers Market?

In November 2023, Alimentiv Inc., a Canada-based clinical research organization specializing in precision-medicine and biomarker services, partnered with AcelaBio Inc. and PharmaNest Inc. to advance artificial intelligence (AI)-enabled digital pathology solutions for non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) clinical trials. With this partnership, Alimentiv aims to integrate high-throughput pathology, spatial transcriptomics, and advanced AI-based biomarker quantification into its offerings. AcelaBio Inc. is a US–based clinical research laboratory accredited by the College of American Pathologists (CAP), and PharmaNest Inc. is a US–based digital pathology and AI technology company specializing in quantitative biomarker analysis.

Regional Outlook

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Non-Alcoholic Steatohepatitis Biomarkers Market?

The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.